Market News AIOpen the app

IRLA stock news · IRulya Therapeutics Inc.

Stories about IRulya Therapeutics Inc. (IRLA) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for IRLA

Follow IRulya Therapeutics Inc. (IRLA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IRLA
Free on the App Store and Google Play, or on the web.
  1. Nov 13, 2026, 4:35 PM ET · Market

    IRulya Therapeutics Inc. reported a $27.7 million loss for the third quarter of 2026.

    Good for IRLA

    IRulya reported $105.2 million in cash and investments, enough to fund work through 2028, with Phase 2 lung-disease data expected in 2027. This supports its drug studies despite a larger loss.

  2. Nov 13, 2026, 9:11 AM ET · Market

    IRulya Therapeutics shared its third quarter 2026 results, showing $105.2 million in cash and investments.

    Good for IRLA

    IRulya reported $105.2 million in cash and expects it to fund operations through 2028. This supports continued work on its drug programs, though trial results are still pending.